Tarsons ProductsQ1 FY27
Tarsons Products Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹347P/E: 155.0Market Cap: ₹1.8K CrSector: Healthcare Equipment & Supplies
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
Yes
Capex
Yes
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Tarsons expects sustainable revenue growth driven by expanded capacities and new product launches, particularly from FY’28 onwards.
- →Domestic market growth targeted at 15%+ year-on-year, with strong Q1 FY’27 performance exceeding 15% growth.
- →New Panchla and Amta facilities expected to contribute 20-25% of standalone revenues by FY’28.
- →Cell culture and other new product lines projected to generate approximately INR 65-70 crores in revenue in FY’28.
- →Exports showing a healthy recovery with 29% Y-o-Y growth in Q1 FY’27 and expected to be a key growth driver, especially through white-labeling.
- →Long-term growth anticipated from greater international presence and integration with Nerbe’s business, including improved product portfolio and geographical expansion.
- →The company aims for 20-25% overall growth combining about 15% from existing products and 5-7% from new products like cell culture lines.
- →Margin improvement expected with better utilization and operating leverage as new capacities ramp up.
Margin guidance
Category 3- →Tarsons expects strong revenue growth driven by ramped-up utilization of expanded capacities and commercialization of new products, especially from FY’28 onwards.
- →EBITDA margins currently impacted by higher raw material costs and new facility expenses are expected to improve with better operating leverage as facilities scale up.
- →Cash profitability grew 18% YoY in Q1 FY’27, showing underlying strength; profits remain moderate in FY’27 due to higher depreciation and interest but will improve subsequently.
- →Growth target includes sustainable 15-22% yearly revenue increase, with 15% from existing products and additional growth driven by new cell culture/product lines.
- →Cell culture and bioprocess products expected to contribute around INR 65-70 crores revenue in FY’28.
- →Government business share is 15-20%, with focus shifting to international markets for margin improvement.
- →Debt expected to reduce INR 40-50 crores this year helping improve interest costs from FY’28 onwards.
3 more insights locked — sign up free to unlock
Fundraise plans
No- →No new major CAPEX plans announced currently; only maintenance CAPEX planned (Page 9).
- →Existing large CAPEX ongoing, with major portion expected to be completed by Q2 or Q3 FY27 (Page 12).
- →Current gross debt approximately INR 380 crores, net debt around INR 330-340 crores (Page 9).
- →Interest run rate expected at INR 20 crores per year in FY27, likely to decrease in FY28 (Page 12).
- →Debt reduction target for FY27 is around INR 40-50 crores, implying active deleveraging (Page 9).
- →No mention of new equity fundraising or fresh debt issuance in the provided transcript.
- →Focus appears to be on completing existing CAPEX and ramping up revenue without additional fundraising.
Order book
Yes- →Export business inquiries are very promising and strong as long as the environment remains conducive to business.
- →Logistics, transportation, and input costs are currently major hurdles, more than tariffs.
- →The company experienced a significant benefit from shipments in the latest quarter, affecting revenue recognition, but shipment schedules remain beyond their control due to global logistic challenges.
- →No specific current order book or pending orders figure is explicitly mentioned in the transcript.
- →The management acknowledges volatile external environments impacting business but remains optimistic on growth.
- →The focus is on building international market base and increasing market share, with some cautiousness due to external factors.
Capex plans
Yes- →Currently in final phase of large-scale capacity expansion program with significant CAPEX already commissioned and operational.
- →Remaining facility commissioning progressing as planned; trial runs underway; full commissioning expected during Q2 FY’27 with revenue contribution starting second half FY’27.
- →No major new CAPEX plans for this year besides maintenance; annual maintenance CAPEX expected around INR 20-25 crores.
- →Anticipate ramp-up revenues from new Panchla and Amta facilities contributing 20-25% to standalone revenues by FY’28.
- →Entire 4-year CAPEX plan expected to enable incremental revenue around INR 400 crores on fixed asset turnover basis, with peak sales potential around INR 750-800 crores.
- →No government grants or incentives engaged for Panchla and Amta CAPEX.
- →Focus shifting from capacity creation to utilization and commercialization to drive sustainable growth.
How does Tarsons Products rank vs peers in Healthcare Equipment & Supplies?
Pro feature1Tarsons Products
Rev 3Mar 3
See full Healthcare Equipment & Supplies sector rankings
How does Tarsons Products rank in Healthcare Equipment & Supplies?
Compare Tarsons Products against every Healthcare Equipment & Supplies company (Q1 FY27) on revenue, margins and earnings-call signals.